<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818725</url>
  </required_header>
  <id_info>
    <org_study_id>GETUG-AFU 19/0903</org_study_id>
    <secondary_id>2009-011882-10</secondary_id>
    <nct_id>NCT02818725</nct_id>
  </id_info>
  <brief_title>I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations</brief_title>
  <acronym>GETUG-AFU19</acronym>
  <official_title>Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES OF THE TRIAL&#xD;
&#xD;
      Primary objective&#xD;
&#xD;
      Evaluation of efficacy in terms of progression-free survival at 9 months of the combination&#xD;
      of intensified methotrexate, vinblastine, doxorubicin and cisplatin with or without&#xD;
      panitumumab as first-line treatment of advanced urothelial carcinoma in patients without&#xD;
      Harvey nor Kirsten rat sarcoma viral oncogene homolog mutations.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  To assess toxicity&#xD;
&#xD;
        -  To assess response rate&#xD;
&#xD;
        -  To assess overall survival&#xD;
&#xD;
        -  To assess time to progression&#xD;
&#xD;
        -  To study the correlation between response rate, time to progression, overall survival&#xD;
           and biological parameters&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2010</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>9 months</time_frame>
    <description>Progression-Free Survival at 9 months post-treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities assessment</measure>
    <time_frame>24 months</time_frame>
    <description>toxicity (CTC AE v4.0) after end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of response</measure>
    <time_frame>24 months</time_frame>
    <description>Recist 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of time to progression</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Infiltrating Urothelial Carcinoma</condition>
  <condition>KRAS Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: chemotherapy + panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin +/- panitumumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>METHOTREXATE: 30 mg/m² on day 1 VINBLASTINE: 3 mg/m² on day 2 DOXORUBICIN: 30 mg/m² on day 2 CISPLATIN: 70 mg/m² on day 2</description>
    <arm_group_label>Arm B: chemotherapy + panitumumab</arm_group_label>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Intensified-Methotrexate Vinblastine Doxorubicin Cisplatin</other_name>
    <other_name>I-MVAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>PANITUMUMAB: 6 mg/kg on day 2</description>
    <arm_group_label>Arm B: chemotherapy + panitumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary tumour of the bladder or upper urinary tract&#xD;
&#xD;
          2. Histologically confirmed infiltrating urothelial carcinoma (epidermoid and/or&#xD;
             glandular forms are accepted)&#xD;
&#xD;
          3. Patients without Harvey and Kirsten-rat sarcoma viral oncogene homolog mutations&#xD;
&#xD;
          4. Advanced disease defined by a locally advanced stage (T4 and/or N+) ineligible for&#xD;
             surgical resection, or a metastatic stage (M1)&#xD;
&#xD;
          5. Patients with at least 1 evaluable lesion as per Response evaluation criteria in solid&#xD;
             tumors version 1.1 (RECIST v1.1)&#xD;
&#xD;
          6. 18 ≤ age ≤ 75 years&#xD;
&#xD;
          7. General condition 0 or 1 as per the WHO scale&#xD;
&#xD;
          8. Absence of previous chemotherapy for advanced disease (chemotherapy with gemcitabine&#xD;
             and platinum salt delivered as an adjuvant is accepted if this ended more than a year&#xD;
             ago)&#xD;
&#xD;
          9. Haematological function: Haemoglobin &gt;11 g/dl, neutrophils ≥1500/mm³, platelets&#xD;
             ≥100,000/mm³&#xD;
&#xD;
         10. Liver function: Grade* 0 Aspartate aminotransferase and Alanine aminotransferase (&lt;&#xD;
             grade* 3 for liver metastases), grade* 0 alkaline phosphatases, normal bilirubin&#xD;
&#xD;
         11. Renal function: calculated (or measured) creatinine clearance &gt;60 ml/min&#xD;
&#xD;
         12. Patients covered by a social security scheme&#xD;
&#xD;
         13. Patient having read the information sheet and signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pure adenocarcinoma or pure epidermoid carcinoma or mixed or pure small-cell&#xD;
             neuroendocrine carcinoma&#xD;
&#xD;
          2. Previous treatment with one of the following molecules: methotrexate, vinblastine,&#xD;
             doxorubicin or Epidermal Growth Factor inhibitor&#xD;
&#xD;
          3. History of interstitial pneumonitis or pulmonary fibrosis&#xD;
&#xD;
          4. History of cardiovascular disease (including myocardial infarction, unstable angina,&#xD;
             symptomatic congestive heart failure, uncontrolled serious cardiac arrhythmia) in the&#xD;
             year prior to randomisation (≤1 year)&#xD;
&#xD;
          5. Ventricular ejection fraction &lt;50%&#xD;
&#xD;
          6. Blood calcium and/or magnesium ≥ grade* 1&#xD;
&#xD;
          7. History of cancer in the 5 years prior to entry in the trial other than basal cell&#xD;
             skin cancer or in situ epithelioma of the cervix,&#xD;
&#xD;
          8. Treatment with radiotherapy for analgesic purposes (unless treatment was discontinued&#xD;
             at least 15 days prior to inclusion in the trial)&#xD;
&#xD;
          9. Potential allergy to panitumumab&#xD;
&#xD;
         10. Male or female patients not agreeing to use an effective method of contraception&#xD;
             throughout the duration of treatment and for 6 months after treatment discontinuation&#xD;
&#xD;
         11. Pregnant women, or female subjects liable to become pregnant or currently&#xD;
             breast-feeding,&#xD;
&#xD;
         12. Patient already included in another therapeutic trial on an investigational medicinal&#xD;
             product,&#xD;
&#xD;
         13. Persons deprived of their freedom or under judicial protection (including&#xD;
             guardianship),&#xD;
&#xD;
         14. Unable to receive medical follow-up during the trial owing to geographical, social or&#xD;
             psychological reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Nimes</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diaconesses - Croix St Simon</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Cancerologie de La Loire</name>
      <address>
        <city>St Priest En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

